Abstract
Background: A series of pyrimidothiadiazinones 5a-n were prepared from aminomethylation of pyrimidinethione 1 with different primary amines and formaldehyde through Mannich reaction. The spectral data of the formed products confirmed the suggested structures.
Method: Most of the newly synthesized compounds were tested for their antimicrobial and anticancer activities. Depending on the obtained results, the newly synthesized compounds possess good to moderate activities. Compound 5e exhibited the highest antibacterial activity measured in 22.1, 18.6, 17.2 and 16.8 mm against Escherichia coli, Staphylococcus aureus, Bacillus subtilis and Pseudomonas aeruginosa, respectively. Compound 5e exhibited highest potency with MIC values of 125, 250, 250, and 500 μg/mL against E. coli, S. aureus, B. subtilis, and P. aureginosa, respectively. Results: Compound 5j exhibited the highest inhibitory effect against breast carcinoma (MCF-7) and hepatocellular carcinoma (HepG2) cell lines. Also, molecular docking against E. Coli Enoyl Reductase; PDB ID (1LXC) and Human Dihydrofolate Reductase; PDB ID (1DLS) revealed high free binding energy and good binding mode. The structure activity relationship (SAR) of tested compounds was also studied.Keywords: Mannich reaction, 1, 3, 5-thiadiazines, molecular docking, antimicrobial and anticancer activities.
Letters in Drug Design & Discovery
Title:Synthesis, Molecular Docking and Pharmacological Study of Pyrimidothiadiazinones and its bis-derivatives
Volume: 14 Issue: 4
Author(s): Sobhi M. Gomha, Ikhlass M. Abbas, Mohamed A. A. Elneairy, Mahmoud M. Elaasser and Bazada K. A. Mabrouk
Affiliation:
Keywords: Mannich reaction, 1, 3, 5-thiadiazines, molecular docking, antimicrobial and anticancer activities.
Abstract: Background: A series of pyrimidothiadiazinones 5a-n were prepared from aminomethylation of pyrimidinethione 1 with different primary amines and formaldehyde through Mannich reaction. The spectral data of the formed products confirmed the suggested structures.
Method: Most of the newly synthesized compounds were tested for their antimicrobial and anticancer activities. Depending on the obtained results, the newly synthesized compounds possess good to moderate activities. Compound 5e exhibited the highest antibacterial activity measured in 22.1, 18.6, 17.2 and 16.8 mm against Escherichia coli, Staphylococcus aureus, Bacillus subtilis and Pseudomonas aeruginosa, respectively. Compound 5e exhibited highest potency with MIC values of 125, 250, 250, and 500 μg/mL against E. coli, S. aureus, B. subtilis, and P. aureginosa, respectively. Results: Compound 5j exhibited the highest inhibitory effect against breast carcinoma (MCF-7) and hepatocellular carcinoma (HepG2) cell lines. Also, molecular docking against E. Coli Enoyl Reductase; PDB ID (1LXC) and Human Dihydrofolate Reductase; PDB ID (1DLS) revealed high free binding energy and good binding mode. The structure activity relationship (SAR) of tested compounds was also studied.Export Options
About this article
Cite this article as:
Gomha M. Sobhi, Abbas M. Ikhlass, Elneairy A. A. Mohamed, Elaasser M. Mahmoud and Mabrouk K. A. Bazada, Synthesis, Molecular Docking and Pharmacological Study of Pyrimidothiadiazinones and its bis-derivatives, Letters in Drug Design & Discovery 2017; 14 (4) . https://dx.doi.org/10.2174/1570180813666160815125409
DOI https://dx.doi.org/10.2174/1570180813666160815125409 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Advantages of Structure-Based Drug Design Approaches in Neurological Disorders
Current Neuropharmacology Nanomedicine based on Nucleic Acids: Pharmacokinetic and Pharmacodynamic Perspectives
Current Pharmaceutical Biotechnology Non-Invasive Approaches to Visualize the Endothelin Axis In Vivo Using State-of-the-Art Molecular Imaging Modalities
Mini-Reviews in Medicinal Chemistry Regulatory T Cells in Central Nervous System: in Health and Disease
Central Nervous System Agents in Medicinal Chemistry The Interaction of Titanocene Y with Double-Stranded DNA: A Computational Study
Letters in Drug Design & Discovery Dutasteride in Androgenetic Alopecia: An Update
Current Clinical Pharmacology Improving Carotenoids and Amino-Acids in Cassava
Recent Patents on Food, Nutrition & Agriculture The Hypothalamic-Pituitary-Adrenal Axis: What can it Tell us About Stressors?
CNS & Neurological Disorders - Drug Targets Ghrelin as a Potential Anti-Obesity Target
Current Pharmaceutical Design Gene Clusters, Molecular Evolution and Disease: A Speculation
Current Genomics Molecular Methods for Individualization of Psychotropic Drug Treatment
Current Pharmacogenomics Dehydroepiandrosterone in Therapy of Allergic Diseases
Recent Patents on Inflammation & Allergy Drug Discovery Interaction of ABC Multidrug Transporters with Anticancer Protein Kinase Inhibitors: Substrates and/or Inhibitors?
Current Cancer Drug Targets Accelerator Production of Scandium Radioisotopes: Sc-43, Sc-44, and Sc-47
Current Radiopharmaceuticals Validation and Development of N-glycan as Biomarker in Cancer Diagnosis
Current Pharmacogenomics and Personalized Medicine Phytochemical Characterization of Prickly Pear (Opuntia spp.) and of its Nutritional and Functional Properties: A Review
Current Nutrition & Food Science Volatilome Metabolomics and Databases, Recent Advances and Needs
Current Metabolomics Cancer Stem Cells Switch on Tumor Neovascularization
Current Molecular Medicine PET Imaging with [<sup>68</sup>Ga]NOTA-RGD for Prostate Cancer: A Comparative Study with [<sup>18</sup>F]Fluorodeoxyglucose and [<sup>18</sup>F]Fluoroethylcholine
Current Cancer Drug Targets Heterogeneity of Cholecystokinin Receptors: A New Interest Towards the Development of CCK2 Agonists
Current Medicinal Chemistry - Central Nervous System Agents